Pharmakon 2007

Evidence based Pharmacy PracticeEvidence based

Pharmacy Practice

Charlotte RossingSection Manager Research

PharmakonDanish College of Pharmacy Practice

Pharmakon 2007

Professional activities at Professional activities at PharmakonPharmakonEducation of

pharmaconomistsCommunity pharmacy/Hospital

pharmacy

Courses

Distance education, e-learning

Textbooks and course materials

Continuing education for pharmaconomistsCommunity pharmacy

Hospital pharmacy

Education in leadership and

organisational development

Training for the pharmaceutical industryVocational training

In-Company training

(unskilled, academic)

Continuing education for pharmacistsCommunity pharmacy

Hospital pharmacy

Pharmaceutical industry/laboratories

Research & development of community pharmacy practice Research and documentationDevelopment of services and methodsConsultancy

International activitiesWHO Collaborating CentreFIP secretariat: Community Pharmacy Section EuroPharm Forum secretariatPCNE: conferences and research projects

Pharmakon 2007

Research and development at PharmakonResearch and development at Pharmakon

Objectives

– To conduct research in pharmacy practice and use of medicines

– To contribute to quality development and documentation of pharmacy services and of the role of the pharmacy in the health care system

Pharmakon 2007

GOOD PHARMACY PRACTICE- WHO and FIP guideline 1996GOOD PHARMACY PRACTICE- WHO and FIP guideline 1996

I. Health promotion and illness prevention

II. Provision of prescription medicines

• Distribution

• Patient information

• Follow up on outcomes (Pharmaceutical Care)

III. Self Care

IV. Influencing prescribing and rational use of drugs

Pharmakon 2007

Agenda Agenda

• Danish Pharmacy Practice Evidence Database

• Asthma-Therapeutic Outcomes Monitoring (TOM)

• Pharmaceutical care for elderly poly-pharmacy patients (OMA)

• Self-medication and self-care

• Safe and effective use of medicines

Pharmakon 2007

The Danish Community Pharmacy Evidence Database

The Danish Community Pharmacy Evidence Database

• The aim of the database is to ensure that the pharmacy sector has access to updated knowledge of the effect of community pharmacy practice in society.

The database contains:

• In total 412 studies (November 2007)

• Evidence reports and individual datasheets for each study (in Danish)

• Summaries and reference lists in English

• Access at: www.pharmakon.com

Pharmakon 2007

The 412 studiesThe 412 studies

– 252 evaluated intervention studies in community pharmacy practice (1990-2005)

– 59 studies on incidence of drug-related problems and adverse drug events in primary care (1990-2005)

– 49 studies on patient safety and medication errors (1990-2005)

– 31 studies on compliance and concordance (1990-2005)

– 21 studies on opportunistic screening in the primary health sector (1995-2005)

Pharmakon 2007

Pharmakon 2007

Pharmakon 2007

Pharmakon 2007

Evidence reports- Intervention studies: structure based on GPP-guideline

Evidence reports- Intervention studies: structure based on GPP-guideline

1. Distribution and prescription handling

2. Patient information on prescribed drugs

3. Follow-up on outcomes of drug therapy (Pharmaceutical Care)

4. Self-care activities

5. Health promotion and ill-health prevention

6. Promoting rational pharmacotherapy to other health professionals

Pharmakon 2007

Evidence reports - Medication safety, risk in drug use and screeningEvidence reports - Medication safety, risk in drug use and screening

7. Incidence of drug-related problems and adverse drug events in primary care

8. Patient safety and medication errors

9. Compliance and concordance

10.Opportunistic screening in the primary health sector

Pharmakon 2007

Report 3 - Pharmaceutical CareReport 3 - Pharmaceutical Care• Follow-up on outcomes of drug therapy

• Medicines management for individual patients

• 1679 abstracts evaluated for inclusion (1990-2005)

• 97 articles evaluated in the report– Europe 33; Canada 10; Australia 11; New

Zealand 1; USA 42

A: 40 Randomized and controlled studies B: 9 Controlled studiesC: 32 Before/after trial without control groupD: 16 Descriptive studies

Pharmakon 2007

Focus on preventing and resolvingdrug related problems (DRP)Focus on preventing and resolvingdrug related problems (DRP)

DRPs leading to risk of lack of effect

1. Untreated indication2. Inappropriate drug3. Too low dosage prescribed/used4. Patient not receiving drug

DRPs leading to risk of adverse effects

5. Too high dosage prescribed/used6. Adverse reactions7. Interactions8. Drug not indicated

Pharmakon 2007

Types of effect measuresTypes of effect measures

• Clinical and health-related indicators• Economic analyses• Satisfaction

• Knowledge/attitude/practice• Drug-related problems• Drug use

• Process indicators

Pharmakon 2007

The ECHO modelThe ECHO model

“Outcomes research in pharmacy practice”

• Economic• Clinical• Humanistic• Outcomes

Kozma 1995

Pharmakon 2007

Report 3 – Pharmaceutical Care- the evidence for medicines management

Report 3 – Pharmaceutical Care- the evidence for medicines management • Pharmaceutical care can improve health related quality of life in

Asthma, BP, BS, Cholesterol. Weaker evidence for the elderly.

• Symptoms are significantly improved in asthma and hypertension.

• Pharmaceutical care can improve clinical measures (BP, BS, Cholesterol)

• Some evidence for reduced hospitalisation and care contacts in elderly

• Health Care costs are reduced; drug costs are unchanged or increased.

• The intervention costs are covered by the cost savings in health care

• The patients enrolled in pharmaceutical care studies are satisfied with the outcome and service.

Pharmakon 2007

Report 3 – Pharmaceutical Care- more evidence

Report 3 – Pharmaceutical Care- more evidence• There are contradicting results on effect on knowledge and

compliance.

• There is evidence of a more positive attitude among the patients towards the pharmacist’s role and competence in the pharmaceutical care process

• There is evidence that drug related problems (DRP) are identified and solved during the pharmaceutical care process

• The quality of drug therapy is improved in asthma and cholesterol, but not documented in elderly programmes

• Process indicators: GP accept rates and patient accept rates are high

• Process descriptors: no. of DRP, recommendations and consultations, time consumption

Pharmakon 2007

Major Danish trials- international and university collaborationMajor Danish trials- international and university collaboration

1. Asthma-Therapeutic Outcomes Monitoring (TOM)

2. Pharmaceutical care for elderly poly-pharmacy patients (OMA)

3. Self-medication and self-care

4. Safe and effective use of medicines

Pharmakon 2007

Purpose for asthma and elderly projects

• To evaluate if pharmaceutical care can improve patients’ health related quality of life, prevent drug related morbidity, and influence use of resources in the health care system

Pharmakon 2007

Participants in asthma and elderly projects

Asthma: 12 months• 16 intervention pharmacies, 15 control pharmacies• 139 GPs• 500 patients med moderate asthma• 10,3 consultations/patient

Elderly: 18 months• 14 intervention pharmacies, 14 control pharmacies• 523 patients: over 65 years, minimum 4 medications• 4,6 consultations/patient

Pharmakon 2007

Asthma services

• Check of : – Peak-flow, inhaler technique, asthma symptoms and

patient perceived problems• Assessment of the total drug therapy• Assessment and monitoring of drug use and compliance• Referral to GP• Counselling on problem solving in everyday life• Education on asthma, medication, and self management

– Instruction in inhaler technique– Instruction in self monitoring: Peak-flow measurement

and use of diary– Instruction in self regulation– Instruction in attacks management

Pharmakon 2007

Results: Asthma program- Intervention group status in relation to controlsResults: Asthma program- Intervention group status in relation to controls

Outcome measures• Better asthma symptom status• Fewer days of illness• Better health related quality of life• Unchanged satisfaction with quality in health care and

pharmacy• Great satisfaction with the program

Process measures• Unchanged peak-flow• Fewer inhalation errors• Better knowledge• More rational drug therapy

Economy• The program was documented to be more cost-effective

Pharmakon 2007

Health economy in asthma program

• Expensive program, more GP contacts• Fewer days of illness, fewer other contacts (incl.

Hospitals), unchanged drug expenses

Economic analysis

• The same effect will cost a factor 5 times less in the intervention group

• Pay-off time: The program will pay itself within a period of 9-23 months, depending on conditions

Pharmakon 2007

Elderly Services• Technical medication review

• Home visit to assess drug storage

• Assessment and monitoring of the drug therapy including simplification and rationalization of dosage regime (as appropriate) in close collaboration with the patient’s GP

• Introduction of methods for home self-monitoring (diary cards)

• Introduction of a medication overview

• Individual patient counselling and education on medical problems and drug use

• Referral to GP if needed

Pharmakon 2007

Results: Elderly program- Intervention group status in relation to controlsResults: Elderly program- Intervention group status in relation to controls

Outcome measures• Better symptom-scores• Fewer hospital admissions, unchanged length of stay• Better health related quality of life• Increased satisfaction with quality in health care and

pharmacy in both groups• Good satisfaction with the program

Process measures• Increased knowledge in both groups – no difference• Unchanged compliance • Fewer problems with use of medicines• More rational drug therapy: number of drugs and doses, few

other changes

Economy• The program was documented to be more cost-effective and

leading to direct savings

Pharmakon 2007

Potential savings in the elderly program

• Net saving per intervention patient in relation to controls:

–2.338 DKr in 18 months

• 20% of elderly people above age 70 use 4 or more drugs

• 140.225 elderly Danes are potential patients in need of the service

• Potential saving: 328 mio. DKr

• Potential saving per year: 219 mio DKr

Pharmakon 2007

Self care and self medication- An extended counselling serviceSelf care and self medication- An extended counselling serviceThe intervention

• A systematic counselling on self-care and self-medication in community pharmacies, aimed at empowering customers by enabling them to make self-care decisions and solve problems in order to obtain better health and well-being

• Individual problem assessment and counselling in relation to 4 key elements: – Response to symptoms – Self-medication and drug related problems– Life-style problems– Patient perceived problems

Pharmakon 2007

Randomised, controlled multi-centre studyRandomised, controlled multi-centre study

• 25 pharmacies randomly assigned to an intervention and a control group aimed at inviting all customers presenting relevant symptoms or drug requests and recruiting 30 patients each.

• Two intervention periods, cross-over design1.Hay fever: Spring 2002 ; 343 intervention/305

control patients2.Dyspepsia: Autumn 2002; 262 intervention/311

control patients

• Evaluation after 2 respectively 4 weeks

• 6 month follow up in dyspepsia group; April 2003

Pharmakon 2007

Summary of resultsSummary of results

• At 4 or 2 weeks health status and symptoms improved significantly in both groups in both dyspepsia and hay fever programs.

• The difference between intervention and control group was significant for dyspepsia. For hay fever only satisfaction with symptoms showed significant difference.

• Satisfaction, knowledge, medicine use, and self care behaviour was significantly better in the intervention group for both programs

• Willingness to pay was significantly higher for the dyspepsia intervention group, no difference was seen for hay fever

• At 6 months dyspepsia patients had significantly improved health outcomes. The difference between intervention and control patients did not persist without any follow up.

Pharmakon 2007

Safe and Effective Use of MedicinesSafe and Effective Use of Medicines

1. “Implementation of drug therapy - Improved adherence and self-management among users of anti-hypertensive medicines”

– Program development and pilot 2004-05– Screening survey and controlled study as demonstration project

from January 2006 to January 2007– Test in 240 patients by 12 pharmacies– Comparing a brief and a comprehensive version of the

intervention.

2. “Safe and effective use of medicines in Type 2-Diabetes”

– Program development 2006– Screening survey and controlled study as demonstration project

from January to June 2007– Test in 80 patients by 5 pharmacies– Brief and comprehensive version

Two Danish research programs

Pharmakon 2007

ObjectivesObjectives

• To develop and evaluate pharmacy based primary care programs aimed at ensuring safe and effective medicine-use among users of Hypertension and Type 2-Diabetes medicines

• To develop patient self management and a concordance-partnership between GPs, pharmacy staff, and non-adherent Hypertension and Type 2 Diabetes patients

• To describe the nature and extent of adherence problems

Pharmakon 2007

Program elementsProgram elements

1. Quick screening for non-adherence and identification of problem types

2. Patient story-telling as the key starting point3. Assessment and possibly adjustment of drug therapy4. Finding resources in the patient-system5. Individual coaching, in order to tailor solutions to

individual needs and resources6. Offering relevant reminder technology and/or patient

instruction7. Follow up8. Close collaboration with patient’s GP

Pharmakon 2007

Effect - HypertensionEffect - Hypertension

Patient reported outcomes at end point

• All differences between intervention- and reference group were statistically significant

• No statistically significant difference was found between the patients receiving the brief or the extended intervention

 Changes in intervention and reference group

• Significant improvement in BP measured by pharmacies for intervention patients

• Significant difference between intervention- and reference group was seen for improvements in patients perceived outcomes on– BP– Knowledge– Health related quality of life– Reduction of symptoms

Pharmakon 2007

Effect - Type 2-DiabetesEffect - Type 2-Diabetes

Patient reported outcomes

• Differences between intervention- and control group show patient reported improvement, many are statistically significant

• Statistically significant difference was found between the patients receiving the brief or the extended intervention

 Changes in intervention and control groups • Significant improvement in BP measured by pharmacies for

intervention patients • Improvement in bloodsugar levels measured by pharmacies for

intervention patients • Significant difference between intervention- and control group

was seen for both services for improvements in– Self reported blood pressure – Knowledge

• Non-significant improvement in self reported adherence behavior (intentional, self-regulation) and QoL

Pharmakon 2007

Conclusions- evidence for clinical pharmacy in primary care?

Conclusions- evidence for clinical pharmacy in primary care?• Implementing clinical pharmacy in primary health

care has had a positive effect for users of medicines

• Community pharmacies are capable of joining the health care team as partners and take a co-responsibility for a successful medication use process as a ‘patient safety filter’

• Clinical pharmacy can be implemented in a cost-effective way in community pharmacies

• The effect can probably be increased by focusing on specific quality problems and by stronger implementation of multidisciplinary collaboration.